01
What the evidence says
In the 68-week industry-funded trial, 1,961 adults with obesity or overweight plus a related condition were randomized in a two-to-one ratio to semaglutide or placebo, both with lifestyle intervention. Mean weight change was about −14.9% with semaglutide and −2.4% with placebo. More participants reached categorical weight-loss thresholds, while gastrointestinal adverse events and treatment discontinuation occurred.
Sources for this section: [1]
02
How to use the finding
Average percentage change should not become a guarantee. People differed in response and harms, and trial visits, eligibility, supply, and behavioral support may not resemble routine care. Decisions should include the person’s health goals, weight-related complications, prior care, pregnancy plans, eating-disorder risk, injection preference, adverse effects, cost, availability, and the possibility of long-term use.
Sources for this section: [1]
03
Limits and open questions
The trial was not designed to prove every long-term clinical outcome, and most participants were women, with limited representation of some populations. The placebo group also received an intervention, so the contrast is not drug versus doing nothing. Later trials and follow-up inform cardiovascular benefit and weight regain, but each question requires its own evidence rather than being inferred from the scale alone.
Sources for this section: [1]
Sources
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · 2021DOI 10.1056/NEJMoa2032183